tetano
Editor, Senior Moderator
J Gastroenterol Hepatol
. 2020 May 21.
doi: 10.1111/jgh.15112. Online ahead of print.
Metabolic Associated Fatty Liver Disease Increases COVID-19 Disease Severity in Non-Diabetic Patients
Feng Gao[SUP] 1 [/SUP], Kenneth I Zheng[SUP] 2 [/SUP], Xiao-Bo Wang[SUP] 3 [/SUP], Hua-Dong Yan[SUP] 4 [/SUP], Qing-Feng Sun[SUP] 5 [/SUP], Ke-Hua Pan[SUP] 6 [/SUP], Ting-Yao Wang[SUP] 7 [/SUP], Yong-Ping Chen[SUP] 2 [/SUP], Jacob George[SUP] 8 [/SUP], Ming-Hua Zheng[SUP] 2 9 10 [/SUP]
Affiliations
Abstract
Background & aims: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients.
Methods: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (?5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis.
Results: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions.
Conclusions: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease.
Keywords: COVID-19; Metabolic associated fatty liver disease; non-diabetes.
This article is protected by copyright. All rights reserved.
. 2020 May 21.
doi: 10.1111/jgh.15112. Online ahead of print.
Metabolic Associated Fatty Liver Disease Increases COVID-19 Disease Severity in Non-Diabetic Patients
Feng Gao[SUP] 1 [/SUP], Kenneth I Zheng[SUP] 2 [/SUP], Xiao-Bo Wang[SUP] 3 [/SUP], Hua-Dong Yan[SUP] 4 [/SUP], Qing-Feng Sun[SUP] 5 [/SUP], Ke-Hua Pan[SUP] 6 [/SUP], Ting-Yao Wang[SUP] 7 [/SUP], Yong-Ping Chen[SUP] 2 [/SUP], Jacob George[SUP] 8 [/SUP], Ming-Hua Zheng[SUP] 2 9 10 [/SUP]
Affiliations
- PMID: 32436622
- DOI: 10.1111/jgh.15112
Abstract
Background & aims: Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether non-diabetic patients with metabolic dysfunction are also more prone to more severe disease. We investigated the association of metabolic associated fatty liver disease (MAFLD) to COVID-19 severity in non-diabetic patients.
Methods: The study cohort comprised 65 patients with- (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (1:1) and age (?5 years). The association between presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis.
Results: In non-diabetic patients with COVID-19, the presence of MAFLD was associated with a 4-fold increased risk of severe COVID-19; the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex and coexisting morbid conditions.
Conclusions: Health care professionals caring for non-diabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with metabolic associated fatty liver disease.
Keywords: COVID-19; Metabolic associated fatty liver disease; non-diabetes.
This article is protected by copyright. All rights reserved.